Candidemia Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis

Candidemia Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Candidemia Market.

The assessment part of the report embraces in-depth Candidemia commercial assessment and clinical assessment of the Candidemia pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Candidemia collaborations, licensing mergers, and acquisition, funding, designations, and other product-related details.

Get FREE sample copy at:

Candidemia Overview

Candidemia is the most common fungal bloodstream infection and possibly the fourth most common all-type bloodstream infection seen in the intensive care unit setting. The incidence of Candida bloodstream infection is bimodal, with the elderly and very young having the highest risk of any population suffering from this disease.

Candidemia Emerging Therapy Assessment:

Some of the major players in the global candidemia market in the late phase of clinical development are Amplyx Pharmaceuticals, Cidara Therapeutics, Scynexis Inc.

  • Rezafungin, also known as CD101 is a novel, once-weekly antifungal being developed for the treatment and prevention of serious fungal infections. 
  • Ibrexafungerp (formerly SCY-078) is the first representative of a novel class of structurally distinct glucan synthase inhibitors, triterpenoids. 
  • Fosmanogepix (APX001) is a pro-drug that is metabolized into its active form manogepix (MGX, formerly APX001A), also known as E1210. 

Candidemia Key Companies:

  1. Amplyx Pharmaceuticals
  2. Cidara Therapeutics
  3. Scynexis

Candidemia Therapies covered in the report include:

  1. APX001
  2. CD101
  3. SCY-078

Report Highlights

  1. A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Candidemia.
  2. In the coming years, the Candidemia market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world, expanding the size of the market to enable the drug manufacturers to penetrate more into the market.
  3. The companies and academics are working to assess challenges and seek opportunities that could influence Candidemia Research & Development. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  4. A detailed portfolio of major pharma players who are involved in fueling the Candidemia treatment market. Several potential therapies for Candidemia are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Candidemia market size in the coming years. 
  5. Our in-depth analysis of the Candidemia pipeline assets (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Get FREE sample copy at:

Table of Contents

  1. Report Introduction
  2. Candidemia 
  3. Candidemia Current Treatment Patterns
  4. Candidemia – DelveInsight’s Analytical Perspective
  5. Therapeutic Assessment
  6. Candidemia Late Stage Products (Phase-III)
  7. Candidemia Mid Stage Products (Phase-II)
  8. Early Stage Products (Phase-I)
  9. Pre-clinical Products and Discovery Stage Products
  10. Inactive Products
  11. Dormant Products
  12. Candidemia Discontinued Products
  13. Candidemia Product Profiles
  14. Candidemia Key Companies
  15. Candidemia Key Products
  16. Dormant and Discontinued Products
  17. Candidemia Unmet Needs
  18. Candidemia Future Perspectives
  19. Candidemia Analyst Review 
  20. Appendix
  21. Report Methodology

*The table of contents is not exhaustive; the final content may vary.

Related Reports:

Candidemia Market

DelveInsight’s “Candidemia Market Insights, Epidemiology and Market Forecast – 2030” report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology as well as the Candidemia Market size and shares analysis for the 7MM (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Candidemia Epidemiology

DelveInsight’s Candidemia – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Candidemia in the 7MM (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Latest Reports By DelveInsight:

Acute Renal Failure Market

DelveInsight’s “Acute Renal Failure (ARF) (Acute Kidney Injury) – Market Insights, Epidemiology, and Market Forecast-2030” report. 

Chronic Hepatitis D Virus Market

DelveInsight’s “Chronic Hepatitis Delta Virus (HDV) Infection – Market Insights, Epidemiology, and Market Forecast-2030” report

Metastatic Colorectal Cancer Market

DelveInsight’s ‘Metastatic Colorectal Cancer (mCRC) Market Insights, Epidemiology and Market Forecast– 2030’ report

Diffuse Intrinsic Pontine Glioma (DIPG) Market

DelveInsight’s “Diffuse Intrinsic Pontine Glioma (DIPG) – Market Insights, Epidemiology, and Market Forecast-2030” report

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Contact Info:

Kritika Rehani

DelveInsight Business Research

Email: [email protected]

Phone No: +91-9650213330


Connect With Us at:

LinkedIn | Facebook | Twitter

Healthcare Blog

Get a Free Sample Copy of the Report at:

Leave a Reply

Your email address will not be published. Required fields are marked *